NT219, a novel dual inhibitor of IRS1/2 and STAT3, is being evaluated in a Phase 2 study in patients with recurrent and/or ...

Despite disruption in the tech space, with mobile-first design and social media becoming increasingly important for brands, print ads still held their own in the 2010s – from deliberate ad fails with ...

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...

IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 immune checkpoint blockade, enhancing immunogenic cell death and T cell ...

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission ...

Critics warned that the Biden administration put so many conditions on the grants it offered to semiconductor manufacturers ...

Dizal will also present results from the ongoing Phase I/II study of DZD6008, a 4th generation EGFR TKI with full BBB penetration, in advanced EGFR mutation positive (EGFRm) non-small cell lung cancer ...

It’s been a fairly grim few years for Ubisoft – buffeted by allegations of an abusive culture, plagued by dismal stock ...

That little girl is Amitis Motevalli, now 55, whose family migrated from Tehran to New York City one year before the Iranian ...

Neurology experts from UCSF Health presented new clinical research findings and cutting-edge treatment strategies and received distinguished awards recognition at the American Academy of Neurology’s ...

Showrunner and creator of 'Ransom Canyon' April Blair unpacked the first season's ending and her ideas for a Season 2.